(NASDAQ:MREO) is up 10% on news of positive phase 2 data.

Statistically significant inhibition of blood neutrophil elastase activity of up to 90% in patients in both high and low dose alvelestat groups throughout the 12-week dosing period

Statistically significant reductions in the biomarkers Aα-val360 and desmosine at the high dose demonstrating clear impact of alvelestat on the pathogenic pathway of AATD-lung disease

No safety signals were associated with alvelestat

Conference Call Today at 10:30 a.m. ET

https://www.globenewswire.com/news-release/2022/05/09/2438434/0/en/Mereo-BioPharma-announces-Positive-Top-Line-Efficacy-and-Safety-Data-from-ASTRAEUS-Phase-2-Trial-of-Alvelestat-in-Alpha-1-Antitrypsin-Deficiency-associated-Emphysema.html

RelatedNews

Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist